Christensen Michael C, Valiente Raul, Sampaio Silva Gisele, Lee Won Chan, Dutcher Sarah, Guimarães Rocha Maria Sheila, Massaro Ayrton
Global Development, Novo Nordisk A/S, Bagsvaerd, Denmark.
Neuroepidemiology. 2009;32(2):142-9. doi: 10.1159/000184747. Epub 2008 Dec 17.
Although stroke is the leading cause of death in Brazil, little information exist on the acute treatment provided for stroke and its associated costs. This study addresses this gap by both clinically and economically characterizing the acute treatment of first-ever intracerebral hemorrhage (ICH) and ischemic stroke (IS) in Brazil.
Retrospective medical chart review using data from two high-volume stroke centers in São Paulo, Brazil. Clinical and resource utilization data for all patients admitted to the stroke centers with a first-ever stroke between January 1, 2006 and May 31, 2007 were collected and the mean acute treatment costs per person were calculated by assigning appropriate unit cost data to all resource use. Cost estimates in Brazilian reals (BRL) were converted to US dollars (USD) using the 2005 purchasing power parity index. National costs of acute treatment for incident strokes were estimated by extrapolation of mean cost estimate per person to national incidence data for the two types of stroke. The mean costs of acute treatment on a national scale were examined in sensitivity analysis.
A total of 316 stroke patients were identified and their demographic and clinical characteristics, patterns of care, and outcomes were examined. Mean length of hospital stay was 12.0 +/- 8.8 days for ICH and 13.3 +/-23.4 days for IS. Ninety-one percent of the ICH patients and 68% of the IS patients were admitted to an intensive care unit (ICU). Mean total costs of initial hospitalization were USD 4,101 (SD +/-4,254) for ICH and USD 1,902 (SD +/-1,426) for IS. In multivariate analysis, hemorrhagic stroke, development of pneumonia, neurosurgical intervention, stay in ICU, and physical therapy were all significant independent predictors of acute treatment costs. Aggregate national health care expenditures for acute treatment of incident ICH were USD 122.4 million (range 30.8-274.2) and USD 326.9 million for IS (range 82.4-732.2).
Acute treatment costs of incident ICH and IS in Brazil are substantial and primarily driven by the intensity of hospital treatment and in-hospital complications. With the expected increase in the incidence of stroke in Brazil over the coming decades, these results emphasize the need for effective preventive and acute medical care.
尽管中风是巴西的主要死因,但关于中风的急性治疗及其相关费用的信息却很少。本研究通过对巴西首次发生的脑出血(ICH)和缺血性中风(IS)的急性治疗进行临床和经济特征分析,填补了这一空白。
利用巴西圣保罗两家大型中风中心的数据进行回顾性病历审查。收集了2006年1月1日至2007年5月31日期间入住中风中心的所有首次中风患者的临床和资源利用数据,并通过为所有资源使用分配适当的单位成本数据来计算每人的平均急性治疗费用。使用2005年购买力平价指数将巴西雷亚尔(BRL)的成本估算转换为美元(USD)。通过将每人的平均成本估算外推到两种中风类型的全国发病率数据,估算了新发中风急性治疗的全国成本。在敏感性分析中检查了全国范围内急性治疗的平均成本。
共识别出316名中风患者,并对他们的人口统计学和临床特征、护理模式及预后进行了检查。ICH患者的平均住院时间为12.0±8.8天,IS患者为13.3±23.4天。91%的ICH患者和68%的IS患者入住了重症监护病房(ICU)。ICH患者首次住院的平均总费用为4,101美元(标准差±4,254),IS患者为1,902美元(标准差±1,426)。在多变量分析中,出血性中风、肺炎的发生、神经外科干预、入住ICU和物理治疗都是急性治疗费用的显著独立预测因素。新发ICH急性治疗的全国医疗保健总支出为1.224亿美元(范围3080万 - 2.742亿美元),IS为3.269亿美元(范围8240万 - 7.322亿美元)。
巴西新发ICH和IS的急性治疗费用很高,主要由住院治疗强度和院内并发症驱动。鉴于未来几十年巴西中风发病率预计会上升,这些结果强调了有效预防和急性医疗护理的必要性。